Cochrane COVID-19 Study Register
AboutHelp
Back to Search Results
NCT04351191

Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate

  1. Study Type
  2. Interventional
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Parallel/Crossover
  1. Intervention Assignment
  2. Randomised
  1. Population (5)
  2. Male and Female
  3. COVID-19
  4. Adult
  1. Intervention (6)
  2. Hydroxychloroquine Sulfate
  3. Therapeutic Intent
  4. Hospital
  1. Comparison (8)
  2. Hydroxychloroquine Sulfate
  3. Chloroquine
  4. Usual Care
  5. Placebo
  6. Therapeutic Intent
  7. Hospital
  1. Outcome (3)
  2. Death
  3. Disease Progression
  4. SARS-CoV-2 RT-PCR

PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds

NCT04351191
First Published (first received 2020)ClinicalTrials.gov (https://clinicaltrials.gov/show/NCT04351191)
Trial registry record
No Results
To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2 infection